Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells 827 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Rebecca Robertson sold 827 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.80, for a total transaction of $14,720.60. Following the sale, the director directly owned 18,749 shares in the company, valued at approximately $333,732.20. The trade was a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

CeriBell Price Performance

Shares of NASDAQ:CBLL traded up $0.02 during trading on Thursday, reaching $17.79. The stock had a trading volume of 165,540 shares, compared to its average volume of 345,835. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.35 and a current ratio of 9.73. CeriBell, Inc. has a 1-year low of $10.01 and a 1-year high of $24.33. The stock has a market cap of $669.63 million, a PE ratio of -12.10 and a beta of 1.12. The business has a fifty day moving average price of $20.91 and a 200-day moving average price of $16.41.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. On average, equities analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CBLL. Caitong International Asset Management Co. Ltd lifted its holdings in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the 3rd quarter worth $33,000. CWM LLC raised its position in CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares during the period. Finally, Ameritas Investment Partners Inc. grew its position in shares of CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after buying an additional 1,256 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. dropped their price target on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. TD Cowen reiterated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. Canaccord Genuity Group upped their price target on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, BTIG Research reissued a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $24.67.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.